Rocket Lab’s $397M Space Force Deal Boosts Backlog but Doesn’t Clear Neutron Hurdle

What happened

Rocket Lab enters its Q2 2026 earnings report with a $397 million U.S. Space Force contract, further expanding a defense backlog that already stood at $2.22 billion as of Q1 2026. This win underscores the company’s successful pivot from a small-launch provider to an integrated space systems contractor, with Space Systems revenue now outpacing Launch Services. However, the near-term investment case remains dominated by Neutron’s Q4 2026 debut and the $8 billion Iridium acquisition financing, neither of which is de-risked by another defense award. The stock trades well above the analyst’s $58 attractive-entry level at $70.4, pricing in successful outcomes that have yet to materialize. Until Neutron stays on track and Iridium funding terms clarify, the contract adds revenue visibility but not enough margin of safety to upgrade the rating.

Implication

Investors should interpret this contract as a reinforcement of Rocket Lab’s position in the defense market, which supports long-term revenue growth but does not alter the near-term risk profile. The current valuation at 67.8x trailing revenue already assumes successful execution of Neutron and a nondilutive Iridium acquisition, making an entry at current levels unattractive. Downside risks remain from potential Neutron delays, fixed-price contract margin pressure, and further equity dilution. The contract extends the backlog duration and underscores customer trust, but free cash flow remains deeply negative, and the company is still dependent on external financing. A more favorable entry point would be closer to $58 or after tangible progress on the two key catalysts.

Thesis delta

The new Space Force award confirms that Rocket Lab’s defense prime ambitions are gaining traction, adding ballast to the backlog-driven part of the thesis. It does not, however, address the binary outcomes tied to Neutron’s maiden launch or the Iridium merger financing, which remain the primary determinants of the stock’s valuation. Therefore, the investment thesis holds at WAIT, with no change in conviction or price targets.